Context Therapeutics (CNTX) Insider Evans Buys 45,000 Shares

Stacey Jennifer Evans purchased 45,000 shares of Context Therapeutics Inc. (NasdaqCM: CNTX) on June 24, 2026. This insider transaction comes as the stock traded near $0.56 on that day.

Insider Buying and Selling at Context Therapeutics Inc.

Several insiders, including Stacey Jennifer Evans, bought 45,000 shares each of Context Therapeutics on June 24, 2026. The transactions were not part of any pre-planned trading arrangements. Other insiders like Karen Smith and Andy Pasternak also participated in similar purchases.

Other Institutional Activity in Context Therapeutics

Soleus Capital Management, L.P. opened a new position in Context Therapeutics with 6,963,141 shares valued at approximately $18.2 million. Similarly, Octagon Capital Advisors LP initiated a stake with 5,250,000 shares worth about $13.8 million. Meanwhile, Blue Owl Capital Holdings LP reduced its holdings by 2,343,891 shares, leaving it with 5,089,015 shares valued at around $13.3 million.

Context Therapeutics Inc. Stock Up 57.6%

On Saturday, shares of Context Therapeutics traded near $0.56. The biopharmaceutical company has a market cap of approximately $51.5 million. It is currently not profitable, so it has no meaningful P/E ratio. The stock's 52-week range is between $0.55 and $3.62, with a 50-day moving average of $2.01 and a 200-day moving average of $1.78. The company maintains a healthy current ratio of 8.96.

Analysts Set New Price Targets

On June 16, 2026, Maxim Group maintained its buy rating on Context Therapeutics, setting a price target of $4.0. The consensus among analysts is a strong buy, with a mean target price of $5.38 based on eight analyst opinions.

About Context Therapeutics

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for solid tumors. Headquartered in Philadelphia, Pennsylvania, the company is led by CEO Martin A. Lehr and employs approximately 15 people. Its key product candidate, CTIM-76, is a bispecific antibody targeting Claudin 6 for cancer therapy. Context Therapeutics collaborates with Integral Molecular, Inc. in developing this therapy.

Bottom Line

Stacey Jennifer Evans' purchase adds to the insider activity at Context Therapeutics, reflecting a vote of confidence in the company. Investors closely follow such insider transactions as potential indicators of the company's prospects. However, these transactions do not provide a current snapshot, as they are reported after the fact.